IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA

IVI offered comments on ICER’s recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis.

In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI’s comments raise a broader question about the relevance of the analysis to decision making. IVI writes that, while ICER’s Draft Evidence Report provides information on the cost-effectiveness of different JAKs relative to adalimumab as the initial treatment of RA patients who have failed on conventional disease-modifying antirheumatic drugs, value assessment should address what is arguably the more relevant question: Given the availability of JAKs, what is the sequence of targeted therapies that provides the most value?

Read the full letter here.